Anti-MOG-associated demyelinating disorders: two sides of the same coin.

Abstract

BACKGROUND:

Anti-myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are new emerging diseases with heterogeneous course, treatment, response, and prognosis.

CASE REPORT:

We herein present 2 cases with antibodies to MOG, one with a cerebellar/brainstem monophasic syndrome which partially improved after treatment, and the other with an optic neuritis onset then relapsed with cortical encephalitis and presented a subsequent complete recovery. We further discuss elements possibly associated with disease heterogeneity and influencing treatment choices.

CONCLUSIONS:

MOGAD is an extremely variable disease which can relapse and accumulate disability over time. An early diagnosis and correct timely treatment is fundamental to improve clinical outcome.

• Authors: Giorgia Teresa Maniscalco, Lia Allegorico, Gennaro Alfieri, Massimo Napolitano, Angelo Ranieri, Rosaria Renna, Giovanna Servillo, Marianna Pezzella, Elisa Capone, Lidia Altomare, Michele Spiniello, Sergio Ferrari, Valentino Manzo, Sara Mariotto
• Journal: Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (Neurol Sci) Vol. 42 Issue 4 Pg. 1531-1534 (Apr 2021) ISSN: 1590-3478 [Electronic] Italy
• PMID: 33190197 (Publication Type: Case Reports, Journal Article)

Chemical References

• Antibodies
• Autoantibodies
• Myelin-Oligodendrocyte Glycoprotein

Topics

• Antibodies
• Autoantibodies
• Demyelinating Diseases (metabolism)
• Encephalitis
• Humans
• Myelin-Oligodendrocyte Glycoprotein
• Optic Neuritis